However, significant limitations exist in the current evidence: Most human data comes from small studies, with limited randomised controlled trials specifically designed to assess alcohol consumption The mechanisms by which GLP-1 medications might reduce alcohol intake are not fully understood Individual responses vary considerably, and not all patients experience changes in drinking behaviour Long-term effects and safety of using these medications specifically for alcohol reduction remain unknown The MHRA has not approved GLP-1 receptor agonists for alcohol use disorder, and these medications should not be considered a treatment for problematic drinking
Obesity Pillars , 17 , 100233
Therefore, we are finalizing our proposal to adopt the Emergency Care Access & Timeliness eCQM
There is no established clinical evidence that semaglutide, tirzepatide, or other GLP-1-based therapies directly create a unique toxin-release syndrome
however, these interventions have long-term feasibility or safety concerns
Directions Wet your face and body with lukewarm water
